Shares of clinical stage biopharmaceutical company, Altimmune, Inc. (ALT) are climbing more than 10% Friday morning at $13.33. It has traded in the range of $1.51- $35.10 in the past 52 weeks.
According to an SEC filing dated September 24, D. E. Shaw & Co., L.P. and David E. Shaw have become beneficial owners of Altimmune taking more than 5% stakes in the company.
Altimmune's investigational therapeutic program for COVID-19 is T-COVID, an intranasal immune modulator for the treatment of outpatients with early COVID-19.
The company is also developing a vaccine for COVID-19 by the name AdCOVID, which is under preclinical studies at the University of Alabama at Birmingham (UAB).
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.